Targeting IL-4 for the Treatment of Atopic Dermatitis

Andrea Chiricozzi, Ketty Peris, Martina Maurelli, Giampiero Girolomoni

Research output: Contribution to journalArticle


Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)-4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4.
Original languageEnglish
Pages (from-to)151-156-156
JournalImmunoTargets and Therapy
Publication statusPublished - 2020


  • IL-4
  • IL-4 inhibitor
  • atopic dermatitis
  • dupilumab
  • pascolizumab
  • pitrakinra


Dive into the research topics of 'Targeting IL-4 for the Treatment of Atopic Dermatitis'. Together they form a unique fingerprint.

Cite this